Abstract Number: 1622 • ACR Convergence 2021
Mind the Gap: The Experience of Adolescents in a Rheumatology Transition Clinic
Background/Purpose: The transition from pediatric to adult healthcare is a critical time for the wellbeing of patients with chronic illness including rheumatologic disease. Low patient…Abstract Number: 0242 • ACR Convergence 2021
FiRst Line Options for Systemic JIA Treatment (FROST): Results from a Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Consensus Treatment Plan Observational Study
Background/Purpose: The optimal initial treatment for systemic juvenile idiopathic arthritis (sJIA) is unclear. To further study the initial treatment of sJIA, the Childhood Arthritis and…Abstract Number: 0262 • ACR Convergence 2021
High Degree of Inter-patient Heterogeneity in Synoviocyte Hyperplasia and Immune Cells Infiltration in the Synovium of Juvenile Idiopathic Arthritis Patients
Background/Purpose: Increasing evidence indicates that synovial tissue analysis can deliver pathophysiological insights but also individual clinically-relevant information in adult-onset inflammatory arthritides. Little is known about…Abstract Number: 1626 • ACR Convergence 2021
Use of Total Hip Arthroplasty in Patients Under 21 Years Old: A U.S. Population Analysis
Background/Purpose: Total hip arthroplasty (THA) is a treatment option for young patients with severe hip pathology due to congenital, developmental, rheumatologic, traumatic, and other acquired…Abstract Number: 0243 • ACR Convergence 2021
Effectiveness of Abatacept in Patients with JIA, Classified by Category: Results from the PRCSG/PRINTO JIA Real-World Registry
Background/Purpose: Long-term treatment with abatacept, a selective T-cell co-stimulation modulator, is effective and well tolerated in patients with JIA.1–4 The objective of this analysis was…Abstract Number: 0263 • ACR Convergence 2021
Patterns of Medication Switching in Juvenile Idiopathic Arthritis: A Retrospective Analysis of a National Administrative Claims Database
Background/Purpose: Although the increasing availability of biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) has significantly improved outcomes for patients with Juvenile Idiopathic…Abstract Number: 1631 • ACR Convergence 2021
Predictive Factors for Lack of Response to Treatment in a Long-term Cohort of Patients with Juvenile Idiopathic Arthritis-associated Uveitis
Background/Purpose: Uveitis is the main extraarticular complication of juvenile idiopathic arthritis (JIA) with still a significant impact on JIA morbidity, despite continuous improvement in systemic…Abstract Number: 0245 • ACR Convergence 2021
Long-term Safety and Effectiveness of Abatacept Treatment in Patients with JIA: 5-year Results from the PRCSG/PRINTO JIA Real-World Registry
Background/Purpose: Abatacept (ABA) is well tolerated and effective in patients with JIA.1 The Pediatric Rheumatology Collaborative Study Group (PRCSG)/ Paediatric Rheumatology INternational Trials Organisation (PRINTO)…Abstract Number: 0264 • ACR Convergence 2021
Joint Acoustic Emissions as a Biomarker to Differentiate Between Active and Inactive Juvenile Idiopathic Arthritis via 2-stage Machine Learning Classifier
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most prevalent chronic rheumatic disease and can result in disability in children. JIA most commonly affects the knee.…Abstract Number: 1639 • ACR Convergence 2021
A Comparison of Cardiovascular Health Indicators in Children with Juvenile Idiopathic Arthritis Who Meet and Do Not Meet the Physical Activity Guidelines
Background/Purpose: Children with juvenile idiopathic arthritis (JIA) engage in less physical activity than their healthy peers. The Canadian 24-h Movement Guidelines recommend children take part…Abstract Number: 0247 • ACR Convergence 2021
Three-year Effectiveness in Patients with JIA Initiating Abatacept: Results from the PRCSG/PRINTO JIA Real-World Registry
Background/Purpose: The ongoing phase 4 Pediatric Rheumatology Collaborative Study Group (PRCSG)/Paediatric Rheumatology INternational Trials Organisation (PRINTO) registry was designed to assess the long-term (up to…Abstract Number: 0265 • ACR Convergence 2021
Development and Preliminary Acceptability of JIActiv, a Social Media-Based Program Promoting Engagement in Physical Activity Among Young People Living with Juvenile Idiopathic Arthritis
Background/Purpose: Young people with juvenile idiopathic arthritis (JIA) are at greater risk for adopting chronic sedentary behaviours and not meeting national physical activity guidelines compared…Abstract Number: 1927 • ACR Convergence 2021
Heterogeneity of Juvenile Idiopathic Arthritis Synovial Fibroblasts Correlates to Disease Progression and Provides Compelling Diagnostic Data
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) induces growth disturbances in affected joints. Fibroblast-like synoviocytes (FLS) play a crucial role in JIA pathogenesis; however, the mechanisms by…Abstract Number: 0248 • ACR Convergence 2021
Proportion of Patients with a Polyphasic Disease Course in Systemic-onset Juvenile Idiopathic Arthritis May Be Higher in the Age of Cytokine Inhibitors
Background/Purpose: Systemic-onset juvenile idiopathic arthritis (sJIA) is a pediatric autoinflammatory condition, known for significant variability between patients in its severity and long-term outcomes. The classification…Abstract Number: 0658 • ACR Convergence 2021
ACCORD: A Novel Rheumatology Transition Clinic Structure for Adolescent and Young Adult Patients with Childhood Onset Rheumatic Disease
Background/Purpose: The transition of health care from Pediatric to Adult providers for adolescents and young adults with childhood onset rheumatic disease continues to be associated…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 20
- Next Page »